A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
216actual
Sites
118
Countries
Argentina, Brazil, China +14
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-07-19 | actual | When the study began enrolling |
| Primary completion | 2024-01-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-29 | estimated | The whole study's end, after follow-up |
| First posted | 2018-05-11 | actual | When this record first appeared on the registry |
| Results posted | 2025-04-03 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non Small Cell Lung Cancer (Stage III)
Interventions
- Drug: Osimertinib 80mg/40mg
- Drug: Placebo Osimertinib 80mg/40mg
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS) by Blinded Independent Central Review (BICR)
measured Every 8 weeks for first 48 weeks, then every 12 weeks until BICR-confirmed radiological disease progression. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-11-03 · 3.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-12-13 · 1.4 MB · SAP_001.pdf
Publications
- PMID 42296617 — linked by the registry
- PMID 42037107 — linked by the registry
- PMID 42019226 — linked by the registry
- PMID 40311309 — linked by the registry
- PMID 39289145 — linked by the registry
- PMID 38828946 — linked by the registry
- PMID 38476120 — linked by the registry
- PMID 33558193 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed